Estrella Immunopharma, Inc. (ESLA) stock
ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.33+0.00 (+0.39%)
Close on Nov 18, 2026Market cap $14.48MP/E –Yield –
Estrella Immunopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Estrella Immunopharma's operating income for the twelve months ending Jun 30, 2024 was -$7.31M. For fiscal 2024 it was -$7.31M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -$7.31M | – |
| FY2021 | Dec 31, 2021 | -$249.15K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ3 2025 | Jun 30, 2026 | -$4.27M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$3.95M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$469.53K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$1.02M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$1.87M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$136.65K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$108.11K | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$3.56K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$819 | – |
See a number that looks wrong?